Asthma, Vitamin D Deficiency
Conditions
Keywords
Asthma, Vitamin D, airway reactivity, metacholine challenge test
Brief summary
Research Title: The effect of vitamin D replacement on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in vitamin D deficient asthmatic children. Introduction: Vitamin D seems to play a role in allergic and asthmatic reactions as an immunomodulator. Asthma disease involves inflammatory process in the lower respiratory tract and airway hyperreactivity. Aim: To assess the effect of Vitamin D replacement on airway reactivity, and allergy and inflammatory mediators in exhaled breath condensate in vitamin D deficient asthmatic children. Design: Double blind placebo control prospective study comparing the effect of Vitamin D replacement and placebo on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in asthmatic pediatric population with vitamin D deficiency. Participant selection: The study group will consist of pediatric patients (age 6-18 years) followed and treated at the Pediatric Pulmonary Unit at the investigators hospital. Patients with mild-moderate asthma with low or insufficient vitamin D levels that are currently not receiving anti-inflammatory treatment will be recruited. Sample size: 60 participants in the two groups (30 receiving Vitamin D and 30 receiving placebo). Intervention: Vitamin D (14000 units) or placebo will be provided in a similar appearance preparation once weekly for 6 weeks between visit two and three. Three visits will be conducted. Each subject will undergo evaluation including a respiratory questionnaire (visit 1), methacholine challenge test with determination of PC20 (visit 1 or 2 and visit 3), exhaled nitric oxide (eNO) (visit 2, 3), and exhaled breath condensate (EBC) (visit 2,3). Venous blood will be analyzed for complete blood count + eosinophils (visit 1, 3), IGE levels (visit 1, 3), and Vitamin D levels (visit 1, 3). Prick skin test for inhaled allergens will be performed (visit 2, 3). Primary end point: Airway reactivity as assessed by methacholine challenge test. Secondary outcome parameters: All other parameters are the secondary end points.
Interventions
drops, 70 drops (= 14000 units), once weekly for 6 weeks
drops, 70 placebo drops, once weekly for 6 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* 6-18 years * Mild-moderate asthma * No anti inflammatory treatment over the past 2 weeks
Exclusion criteria
* Any Chronic Lung Disease * Febrile Illness in last 2 weeks * FEV1 \< 65% in study day * Bronchodilators over the past 24 hours prior to each study * Participation in any other clinical studies over the past 4 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metacholine Challenge Test | study visit 1,3 (6wks- 3 months) | As assessed by methacholine challenge test with determination of PC20. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IGE | study visit 1,3 (6wks- 3 months) | in peripheral Blood count |
| CBC | study visit 1,3 (6wks- 3 months) | in peripheral Blood count |
| Fractional Exhaled NO | visit study 2,3 (6wks) | determination of exhaled NO in Exhaled breath |
| skin tests for inhaled allergens | visit study 2,3 (6wks) | — |
| Exhaled breath condensate | visit study 2,3 (6wks) | R-tubes test |
Countries
Israel